Trial Profile

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab/pembrolizumab (Primary) ; Irinotecan (Primary) ; Lenvatinib (Primary) ; MK-4830 (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms KEYMAKER-U06; Substudy 06A
Sponsors Merck Sharp & Dohme

04 Apr 2025 Planned End Date changed from 21 Sep 2026 to 13 Nov 2025.
04 Apr 2025 Planned primary completion date changed from 27 Mar 2025 to 13 Nov 2025.
10 Feb 2025 Planned primary completion date changed from 30 Jan 2025 to 27 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com